These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 27110777

  • 41. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
    Liu CG, Luo QX, Ling TY, Mo YY, Cheng ZL, Huang SG, Mo H.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
    [Abstract] [Full Text] [Related]

  • 42. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ.
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [Abstract] [Full Text] [Related]

  • 43. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ, Ji ZL, Chen SM.
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [Abstract] [Full Text] [Related]

  • 44. Effects of intermedin on proliferation, apoptosis and the expression of OPG/RANKL/M-CSF in the MC3T3-E1 osteoblast cell line.
    Ren H, Ren H, Li X, Yu D, Mu S, Chen Z, Fu Q.
    Mol Med Rep; 2015 Nov; 12(5):6711-7. PubMed ID: 26398911
    [Abstract] [Full Text] [Related]

  • 45. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.
    Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.
    Biochem Biophys Res Commun; 2006 Aug 25; 347(2):460-7. PubMed ID: 16828054
    [Abstract] [Full Text] [Related]

  • 46. Involvement of the Ca²⁺ signaling pathway in osteoprotegerin inhibition of osteoclast differentiation and maturation.
    Fu Y, Gu J, Wang Y, Yuan Y, Liu X, Bian J, Liu ZP.
    J Vet Sci; 2015 Aug 25; 16(2):151-6. PubMed ID: 25549213
    [Abstract] [Full Text] [Related]

  • 47. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
    Aoyama E, Kubota S, Khattab HM, Nishida T, Takigawa M.
    Bone; 2015 Apr 25; 73():242-8. PubMed ID: 25554597
    [Abstract] [Full Text] [Related]

  • 48. Antiosteoclastic bone resorption activity of osteoprotegerin via enhanced AKT/mTOR/ULK1-mediated autophagic pathway.
    Zhao H, Sun Z, Ma Y, Song R, Yuan Y, Bian J, Gu J, Liu Z.
    J Cell Physiol; 2020 Mar 25; 235(3):3002-3012. PubMed ID: 31535378
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH, Chang EJ, Kim SJ, Kim HH, Kim HM, Lee SB, Ko JS.
    J Periodontal Res; 2006 Aug 25; 41(4):288-96. PubMed ID: 16827722
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading.
    You L, Temiyasathit S, Lee P, Kim CH, Tummala P, Yao W, Kingery W, Malone AM, Kwon RY, Jacobs CR.
    Bone; 2008 Jan 25; 42(1):172-9. PubMed ID: 17997378
    [Abstract] [Full Text] [Related]

  • 53. Dual modulation of osteoclast differentiation by lipopolysaccharide.
    Zou W, Bar-Shavit Z.
    J Bone Miner Res; 2002 Jul 25; 17(7):1211-8. PubMed ID: 12096834
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Osteoblasts stimulate osteoclastogenesis via RANKL expression more strongly than periodontal ligament cells do in response to PGE(2).
    Mayahara K, Yamaguchi A, Takenouchi H, Kariya T, Taguchi H, Shimizu N.
    Arch Oral Biol; 2012 Oct 25; 57(10):1377-84. PubMed ID: 22884709
    [Abstract] [Full Text] [Related]

  • 56. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption.
    Peng S, Liu XS, Zhou G, Li Z, Luk KD, Guo XE, Lu WW.
    J Bone Miner Res; 2011 Jun 25; 26(6):1272-82. PubMed ID: 21611968
    [Abstract] [Full Text] [Related]

  • 57. The role of parathyroid hormone-related protein in the regulation of osteoclastogenesis by cementoblasts.
    Boabaid F, Berry JE, Koh AJ, Somerman MJ, McCcauley LK.
    J Periodontol; 2004 Sep 25; 75(9):1247-54. PubMed ID: 15515341
    [Abstract] [Full Text] [Related]

  • 58. Osteoblasts of calvaria induce higher numbers of osteoclasts than osteoblasts from long bone.
    Wan Q, Schoenmaker T, Jansen ID, Bian Z, de Vries TJ, Everts V.
    Bone; 2016 May 25; 86():10-21. PubMed ID: 26921824
    [Abstract] [Full Text] [Related]

  • 59. Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.
    Roato I, Porta F, Mussa A, D'Amico L, Fiore L, Garelli D, Spada M, Ferracini R.
    PLoS One; 2010 Nov 30; 5(11):e14167. PubMed ID: 21152388
    [Abstract] [Full Text] [Related]

  • 60. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
    Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB.
    Arthritis Rheum; 2004 Dec 30; 50(12):3831-43. PubMed ID: 15593184
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.